Literature DB >> 17573419

Lipoprotein-associated phospholipase A2 predicts 5-year cardiac mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (the Ludwigshafen risk and cardiovascular health study).

Karl Winkler1, Michael M Hoffmann, Bernhard R Winkelmann, Isolde Friedrich, Günther Schäfer, Ursula Seelhorst, Britta Wellnitz, Heinrich Wieland, Bernhard O Boehm, Winfried März.   

Abstract

BACKGROUND: Lipoprotein-associated phospholipase A(2) (LpPLA(2)), also denoted as platelet-activating factor acetylhydrolase, is a lipoprotein-bound enzyme involved in inflammation and atherosclerosis. In this cohort study we investigated LpPLA(2) activity to predict cardiac mortality in patients scheduled for coronary angiography.
METHODS: LpPLA(2) activity was determined in 2513 patients with and in 719 patients without angiographically confirmed coronary artery disease (CAD).
RESULTS: During the median observation period of 5.5 years, 501 patients died. In patients with tertiles of LpPLA(2) activity of 420-509 U/L or >or=510 U/L, unadjusted hazard ratios (HRs) for cardiac death were 1.7 (95% CI 1.3-2.4; P = 0.001), and 1.9 (95% CI 1.4-2.5; P <0.001), respectively, compared with patients with LpPLA(2) activity <or=419 U/L. After we accounted for established risk factors and included angiographic CAD status, high-sensitivity C-reactive protein (hsCRP), and N-terminal pro-B-type natriuretic peptide, the 3rd tertile of LpPLA(2) activity predicted cardiac 5-year mortality with an HR of 2.0 (95% CI 1.4-3.1; P = 0.001). LpPLA(2) activity increased the adjusted risk for cardiac death by 2-fold in patients with hsCRP <3 mg/L in the 2nd (HR 2.4, 95% CI 1.4-4.2; P = 0.002) and 3rd (HR 2.1, 95% CI 1.1-4.0; P = 0.02) tertiles of LpPLA(2) activity and in patients with hsCRP of 3-10 mg/L in the 3rd tertile (HR 1.9, 95% CI 1.0-3.6; P = 0.03) of LpPLA(2) activity.
CONCLUSIONS: LpPLA(2) activity predicts risk for 5-year cardiac mortality independently from established risk factors and indicates risk for cardiac death in patients with low and medium-high hsCRP concentrations. Therefore, LpPLA(2) activity may provide information for the identification and management of patients at risk beyond established risk stratification strategies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17573419     DOI: 10.1373/clinchem.2007.086298

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  15 in total

Review 1.  Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2.

Authors:  Robert S Rosenson; Diana M Stafforini
Journal:  J Lipid Res       Date:  2012-06-04       Impact factor: 5.922

2.  Use of biomarkers to develop treatment strategies for atherosclerosis.

Authors:  Mark A Crandall; Marshall A Corson
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-08

3.  Lipoprotein-associated phospholipase A2 and cardiovascular disease risk in HIV infection.

Authors:  A Ross Eckard; C T Longenecker; Y Jiang; S M Debanne; D Labbato; N Storer; G A McComsey
Journal:  HIV Med       Date:  2014-03-20       Impact factor: 3.180

Review 4.  Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention.

Authors:  Edward A Dennis; Jian Cao; Yuan-Hao Hsu; Victoria Magrioti; George Kokotos
Journal:  Chem Rev       Date:  2011-09-12       Impact factor: 60.622

Review 5.  Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complications.

Authors:  Giuseppe Maiolino; Valeria Bisogni; Giacomo Rossitto; Gian Paolo Rossi
Journal:  World J Cardiol       Date:  2015-10-26

Review 6.  Lipoprotein-associated phospholipase A2 as a novel risk marker for cardiovascular disease: a systematic review of the literature.

Authors:  Mohammad Madjid; Muzammil Ali; James T Willerson
Journal:  Tex Heart Inst J       Date:  2010

7.  Nonsynonymous polymorphisms in PLA2G7 gene are associated with the risk of coronary heart disease in a southern Chinese population.

Authors:  Mei Hong; Mengyao Zhang; Xiang Lu
Journal:  Mamm Genome       Date:  2015-02-18       Impact factor: 2.957

8.  Association of lipoprotein-associated phospholipase A2 with coronary artery disease in African-Americans and Caucasians.

Authors:  Erdembileg Anuurad; Zeynep Ozturk; Byambaa Enkhmaa; Thomas A Pearson; Lars Berglund
Journal:  J Clin Endocrinol Metab       Date:  2010-03-01       Impact factor: 5.958

9.  Systematic Review of the Association between Lipoprotein-Associated Phospholipase A2 and Atherosclerosis.

Authors:  Jing Liu; Yuling Hong; Yue Qi; Fan Zhao; Dong Zhao
Journal:  N Am J Med Sci (Boston)       Date:  2011-10

10.  Lipoprotein-associated phospholipase A2 activity predicts cardiovascular events in high risk coronary artery disease patients.

Authors:  Giuseppe Maiolino; Luigi Pedon; Maurizio Cesari; Anna Chiara Frigo; Robert L Wolfert; Marlena Barisa; Leopoldo Pagliani; Giacomo Rossitto; Teresa Maria Seccia; Mario Zanchetta; Gian Paolo Rossi
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.